SavedAdd your journal

Journals / Düzce Tıp Fakültesi Dergisi / 2010 / Cilt: 12 - Sayı: 1

Drugs Induced Stevens-Johnson Syndrome

İlaçlara Bağlı Stevens-Johnson Sendromu

Hülya ALBAYRAK
Zehra GÜRLEVİK
Yusuf AYDIN
Elif ÖNDER
Pages
98–103
Publication Date
2010-03-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We hereinreport a short review of drug induced SJS and its treatment

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Stevens Johnson Syndrome (SJS) is a life threatening mucocutaneous skin disease that mostlydeveloped after using some drug.
📊
Key Findings & Data:SJS mostly appear between 2-4th decades.
💡
Conclusion & Impact:We hereinreport a short review of drug induced SJS and its treatment
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Stevens Johnson Sendromu · İlaçlar · Stevens Johnson Syndrome

Abstract

Stevens Johnson Syndrome (SJS) is a life threatening mucocutaneous skin disease that mostlydeveloped after using some drug. SJS mostly appear between 2-4th decades. Mucocutaneouslesions were seen between 1-14 days of drug intake. And these lesions spread diffusely all aroundthe body. First treatment choice is the stopping of drug that cause SJS and giving supportingtreatment. After understanding of underlying cytotoxic and immunological mechanism of SJS,new treatment approaches were developed and mortality of disease was reduced. We hereinreport a short review of drug induced SJS and its treatment

Özet

Stevens Johnson Sendromu (SJS) sıklıkla ilaçlara bağlı olarak gelişen nadir fakat hayatı tehditedebilen mukokutanöz bir cilt reaksiyonudur. Her yaşta ortaya çıkabilmekle birlikte en sık 2–4. dekatlarda görülür. Mukokutanöz lezyonlar, sebep olan ilacın alınmasını takiben 1–14 günlükdöneminin ardından ortaya çıkar. Gövde ve yüzde başlayan eritematöz makülopapülerdöküntüler hızla tüm vücuda yayılır. Tedavisinde ilk basamak, sebep olan ilacın kesilmesi vedestek tedavisidir. Günümüzde altta yatan sitotoksik ve immünolojik mekanizmaların daha iyianlaşılması yeni tedavi yaklaşımlarının ortaya çıkmasını ve mortalitenin azalmasını sağlamıştır.Bu yazıda ilaçlara bağlı olarak gelişen SJS hakkında kısa bir derleme sunulmaktadır

🔖

Cite This Article

ALBAYRAK, H., GÜRLEVİK, Z., AYDIN, Y., ÖNDER, E. (2010). Drugs Induced Stevens-Johnson Syndrome. Düzce Tıp Fakültesi Dergisi, Cilt: 12 - Sayı: 1, 98–103. https://ajindex.com/articles/420446

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Hussain W, Craven NM: Toxic epidermal necrolysis and Stevens-Johnson syndrome. Clin Med. 5:555–558, 2005.
  2. Stevens AM, Johnson PC: A new eruptive fever assosiated with stomatitis and ophtalmica: report of two cases in children. Am J Dis Child. 24: 526-533, 1922.
  3. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC: Clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome, and erythema multiforme. Arch Dermatol. 129:92–96, 1993.
  4. Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R: Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother. 39:162–164, 2005.
  5. Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME: Stevens–Johnson syndrome and toxic epidermal necrolysis. Autoimmunity Reviews 7.598–605, 2008.
  6. Famularo G, De Simone C, Minisola G: Stevens-Johnson syndrome associated with single high dose of lamotrigine in a patient taking valproate. Dermatol Online J.11:25. 2005.
  7. Levy M, Shear NH: Mycoplasma pneumoniae infections and Stevens Johnson syndrome: report of eight cases and review of the literature. Clin Pediatr.30:42–49, 1991.
  8. Ravin KA, Rappaport LD, Zuckerbraun NS, Wadowsky RM, Wald ER, Michaels MM: Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome: a case series. Pediatrics. 119:1002–1005, 2007
  9. Hanno R, Bean SF: Hodgkin’s disease with specific bullous lesions. Am J Dermatopathol. 2:363–366, 1980.
  10. Margolis RJ, Bhan A, Mihm MC Jr, Bernhardt M: Erythema multiforme in a patient with T cell chronic lymphocytic leukemia. J Am Acad Dermatol. 14:618–627, 1986.
  11. Hazin R, Ibrahimi OA, Hazin MI, Kimyai-Asadi A: Stevens- Johnson syndrome: Pathogenesis, diagnosis, and management. Ann Medicine. 40:129-1382008.
  12. Rzany B, Mockenhaupt M, Stocker U, Hamouda O, Schöpf E: Incidence of Stevens Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch. Dermatol. 129:1059, 1993. Roujeau JC: Clinical heterogeneity of drug hypersensitivity. Toxicology. 209:123–129, 2005.
  13. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 66:233–243, 1991.
  14. Iwai K, Miyawaki T, Takizawa T, Konno A, Ohta K, Yachie A, Seki H, Taniguchi N: Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blo